Therapeutic cancer vaccines: are we there yet?

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Sorafenib in advanced hepatocellular carcinoma

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846 · cited 8×

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Petrylak, D. P., Tangen, C. M., Hussain, M., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D. L., Moinpour, C. M., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645

Vaccines for colorectal cancer: an update

Sarvizadeh, M., Ghasemi, F., Tavakoli, F., Khatami, S. S., Razi, E., Sharifi, H., Mousavi, N., & Taghizadeh, M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28179 · Cited by 41

Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine

Gigoux, M., Holmström, M. O., Zappasodi, R., Park, J. J., Pourpe, S., Bozkus, C. C., Mangarin, L. M. B., Redmond, D., Verma, S., Schad, S. E., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4380 · Cited by 41

At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias

Norell, H., Moretta, A., Silva‐Santos, B., & Moretta, L. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0613312 · Cited by 41

Adoptive immunotherapy against ovarian cancer

Mittica, G., Capellero, S., Genta, S., Cagnazzo, C., Aglietta, M., Sangiolo, D., & Valabrega, G. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0236-9 · Cited by 40

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37

Beyond the Antigen Receptor: Editing the Genome of T-Cells for Cancer Adoptive Cellular Therapies

Lloyd, A., Vickery, O. N., & Laugel, B. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00221 · Cited by 36

Vaccination with Antigen-Transfected, NKT Cell Ligand–Loaded, Human Cells Elicits Robust In Situ Immune Responses by Dendritic Cells

Shimizu, K., Mizuno, T., Shinga, J., Asakura, M., Kakimi, K., Ishii, Y., Masuda, K., Maeda, T., Sugahara, H., Sato, Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0759 · Cited by 37

A Stressful Microenvironment: Opposing Effects of the Endoplasmic Reticulum Stress Response in the Suppression and Enhancement of Adaptive Tumor Immunity

Rausch, M. P., & Sertil, A. R. (2015) · International Reviews of Immunology · doi:10.3109/08830185.2015.1018415 · Cited by 35

Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8 + T-cell responses and prevent tumour progression

Neumann, S., Young, K., Compton, B. J., Anderson, R. J., Painter, G. F., & Hook, S. M. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.08.083 · Cited by 36

Harnessing DNA-induced immune responses for improving cancer vaccines

Herrada, A. A., Rojas-Colonelli, N., González-Figueroa, P., Roco, J. A., Oyarce, C., Ligtenberg, M. A., & Lladser, Á. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22345 · Cited by 37

Biomarkers in T cell therapy clinical trials

Kalos, M. D. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-138 · Cited by 36

Rational combination immunotherapeutic approaches for effective cancer treatment

Phung, C. D., Nguyen, H. T., Tran, T. H., Choi, H., Yong, C. S., & Kim, J. O. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.020 · Cited by 35

Striking a Balance—Cellular and Molecular Drivers of Memory T Cell Development and Responses to Chronic Stimulation

Hope, J. L., Stairiker, C. J., Bae, E., Otero, D. C., & Bradley, L. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01595 · Cited by 38

Postexposure Effects of Vaccines on Infectious Diseases

Gallagher, T., & Lipsitch, M. (2019) · Epidemiologic Reviews · doi:10.1093/epirev/mxz014 · Cited by 35

Breaking immunotolerance of tumors: A new perspective for dendritic cell therapy

Roliński, J., & Hus, I. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.865094 · Cited by 34

Collagen I enhances functional activities of human monocyte-derived dendritic cells via discoidin domain receptor 2

Poudel, B., Yoon, D.-S., Lee, J.-H., Lee, Y., & Kim, D. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.07.004 · Cited by 34

Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?

Hu, L., Lan, H., Huang, D., Li, X., & Jin, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769305 · Cited by 34

Optimizing vaccine-induced CD8+T-cell immunity: focus on recombinant adenovirus vectors

Bassett, J. D., Swift, S. L., & Bramson, J. L. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.88 · Cited by 34

At the bench: Engineering the next generation of cancer vaccines

Shae, D., Baljon, J. J., Wehbe, M., Becker, K. W., Sheehy, T. L., & Wilson, J. T. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.5bt0119-016r · Cited by 32

Telomerase and CD4 T Cell Immunity in Cancer

Dosset, M., Castro, A., Carter, H. K., & Zanetti, M. (2020) · Cancers · doi:10.3390/cancers12061687 · Cited by 33

Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity

Erkes, D. A., Xu, G., Daskalakis, C., Zurbach, K. A., Wilski, N. A., Moghbeli, T., Hill, A. B., & Snyder, C. M. (2016) · Molecular Therapy · doi:10.1038/mt.2016.121 · Cited by 30

Translation dysregulation in cancer as a source for targetable antigens

Weller, C., Bartok, O., McGinnis, C. S., Palashati, H., Chang, T., Malko, D. B., Shmueli, M. D., Nagao, A., Hayoun, D., Murayama, A., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.003 · Cited by 32

Melanoma vaccines: clinical status and immune endpoints

Maurer, D. M., Butterfield, L. H., & Vujanovic, L. N. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000535 · Cited by 32

Regulatory T cells in gastrointestinal tumors

Raghavan, S., & Quiding‐Järbrink, M. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.44 · Cited by 29

Photonics immunotherapy — A novel strategy for cancer treatment

Zhou, F., Nordquist, R. E., & Chen, W. R. (2015) · Journal of Innovative Optical Health Sciences · doi:10.1142/s1793545816300019 · Cited by 29

Immunological monitoring of the tumor immunoenvironment for clinical trials

Malyguine, A. M., Strobl, S. L., & Shurin, M. R. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1148-6 · Cited by 27

Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141+ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8+ T Cell Response in Human Immune System Mice

Huang, J., Zhou, J., Ghinnagow, R., Seki, T., Iketani, S., Soulard, D., Paczkowski, P., Tsuji, Y., Mackay, S., Cruz, L. J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02043 · Cited by 27

Anti-Tumor Efficacy of In Situ Vaccination Using Bacterial Outer Membrane Vesicles

Caproni, E., Corbellari, R., Tomasi, M., Isaac, S. J., Tamburini, S., Zanella, I., Grigolato, M., Gagliardi, A., Benedet, M., Baraldi, C., et al. (2023) · Cancers · doi:10.3390/cancers15133328 · Cited by 27

Intratumoral infection by CMV may change the tumor environment by directly interacting with tumor-associated macrophages to promote cancer immunity

Erkes, D. A., Wilski, N. A., & Snyder, C. M. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1331795 · Cited by 27

Beyond Cancer Vaccines

Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823261db · Cited by 26

Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity.

Tian, S., Liu, Z.-Q., Donahue, C., Falo, L., & You, Z. (2012) · Molecular Therapy · doi:10.1038/mt.2011.183 · Cited by 23

Nanocarriers, nanovaccines, and nanobacteria as nanobiotechnological concerns in modern vaccines

Gill, P. (2013) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · doi:10.1016/j.scient.2013.05.012 · Cited by 25

Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma

Rodriguez, A. B., Peske, J. D., & Engelhard, V. H. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8709-2_14 · Cited by 25

Improving the Therapeutic Potential of Human Granzyme B for Targeted Cancer Therapy

Hehmann-Titt, G., Schiffer, S., Berges, N., Melmer, G., & Barth, S. (2013) · Antibodies · doi:10.3390/antib2010019 · Cited by 24

Hematologic neoplasms: Dendritic cells vaccines in motion

Galati, D., & Zanotta, S. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.08.016 · Cited by 25

Hobit and human effector T‐cell differentiation: The beginning of a long journey

Braun, J., Frentsch, M., & Thiel, A. (2015) · European Journal of Immunology · doi:10.1002/eji.201545959 · Cited by 24

The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018

Dahl, O., & Brydøy, M. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1555375 · Cited by 24

Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8+ T Cell Responses with Antitumor Activity

Booty, M. G., Hlavaty, K. A., Stockmann, A. P., Ozay, E. I., Smith, C. K., Tian, L., How, E., Subramanya, D., Venkitaraman, A., Yee, C., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100656 · Cited by 23

Selected anti-tumor vaccines merit a place in multimodal tumor therapies

Weiss, E., Wunderlich, R., Ebel, N., Rubner, Y., Schlücker, E., Meyer‐Pittroff, R., Ott, O. J., Fietkau, R., Gaipl, U. S., & Frey, B. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00132 · Cited by 23

Adoptive T-cell Transfer in Melanoma

Itzhaki, O., Levy, D., Zikich, D., Treves, A. J., Markel, G., Schachter, J., & Besser, M. J. (2012) · Immunotherapy · doi:10.2217/imt.12.143 · Cited by 24

T‐cell receptor gene therapy — ready to go viral?

Kärpänen, T., & Olweus, J. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.006 · Cited by 23

Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth

Bryson, P. D., Han, X., Truong, N., & Wang, P. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.09.017 · Cited by 23

Informatics for cancer immunotherapy

Hammerbacher, J., & Snyder, A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx682 · Cited by 23

Self-assembling, self-adjuvanting and fully synthetic peptide nanovaccine for cancer immunotherapy

Song, H., Su, Q., Huang, P., Zhang, C., & Wang, W. (2021) · Smart Materials in Medicine · doi:10.1016/j.smaim.2021.07.007 · Cited by 22

Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb

Uehara, J., Ohkuri, T., Kosaka, A., Ishibashi, K., Hirata, Y., Ohara, K., Nagato, T., Oikawa, K., Aoki, N., Harabuchi, Y., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.072 · Cited by 22

Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy

Ghinnagow, R., Cruz, L. J., Fernandez, É. M., Faveeuw, C., & Trottein, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00879 · Cited by 22

Radiotherapy in the age of cancer immunology: Current concepts and future developments

Loi, M., Desideri, I., Greto, D., Mangoni, M., Sottili, M., Meattini, I., Becherini, C., Terziani, F., Paoli, C. D., Olmetto, E., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.002 · Cited by 23

Immunokinases, a Novel Class of Immunotherapeutics for Targeted Cancer Therapy

Tur, M. K., Neef, I., Jäger, G., Teubner, A., Stocker, M., Melmer, G., & Barth, S. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788923877 · Cited by 20

Reporter Gene Imaging of Immune Responses to Cancer: Progress and Challenges

Dubey, P. (2012) · Theranostics · doi:10.7150/thno.3903 · Cited by 21

Commensal Bifidobacterium Strains Enhance the Efficacy of Neo-Epitope Based Cancer Vaccines

Tomasi, M., Dalsass, M., Beghini, F., Zanella, I., Caproni, E., Fantappiè, L., Gagliardi, A., Irene, C., König, E., Frattini, L. F., et al. (2021) · Vaccines · doi:10.3390/vaccines9111356 · Cited by 18

Development of Immune-Specific Interaction Potentials and Their Application in the Multi-Agent-System VaccImm

Woelke, A. L., von Eichborn, J., Murgueitio, M. S., Worth, C. L., Castiglione, F., & Preißner, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023257 · Cited by 20

Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma

Tomei, S., Wang, E., Delogu, L. G., Marincola, F. M., & Bedognetti, D. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.890586 · Cited by 22

Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response

Khong, H., Volmari, A., Sharma, M., Dai, Z., Imo, C. S., Hailemichael, Y., Singh, M., Moore, D. T., Xiao, Z., Huang, X.-F., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700467 · Cited by 20

Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer

Domínguez‐Romero, A. N., Zamora-Alvarado, R., Servín-Blanco, R., Pérez-Hernández, E. G., Castrillón-Rivera, L. E., Munguía, M. E., Acero, G., Govezensky, T., Gevorkian, G., & Manoutcharian, K. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29679 · Cited by 20

Synthesis and Evaluation of QS-21-Based Immunoadjuvants with a Terminal-Functionalized Side Chain Incorporated in the West Wing Trisaccharide

Wang, P., Devalankar, D. A., Dai, Q., Zhang, P., & Michalek, S. M. (2016) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6b00922 · Cited by 20

Anti-tumour effects of a xenogeneic fibroblast activation protein-based whole cell tumour vaccine in murine tumour models

Chen, M., Xu, G., Fan, M., Jia, H., Xiao, L., & Lang, J. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1687498 · Cited by 19

Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008

Janowitz, T., Lu, L., Yan, H., & Shyam-Sundar, V. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s65963 · Cited by 19

Potential of bacterial outer membrane vesicles in tumor vaccine: characteristics, advancements, and future directions

Yang, Y., & Wu, Y. (2025) · Essays in Biochemistry · doi:10.1042/ebc20253004 · Cited by 18

Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML

Fujii, S., Kawamata, T., Shimizu, K., Nakabayashi, J., Yamasaki, S., Iyoda, T., Shinga, J., Nakazato, H., Sanpei, A., Kawamura, M., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.09.001 · Cited by 18

Differential requirements of CD 4+ T ‐cell signals for effector cytotoxic T‐lymphocyte ( CTL ) priming and functional memory CTL development at higher CD 8+ T ‐cell precursor frequency

Umeshappa, C. S., Nanjundappa, R. H., Xie, Y., Freywald, A., Xu, Q., & Xiang, J. (2012) · Immunology · doi:10.1111/imm.12033 · Cited by 18

ZnO nanoparticles stimulate oxidative stress to induce apoptosis of B16F10 melanoma cells: In vitro and in vivo studies

Fan, P., Yang, C., Wang, L., Wang, Q., Zhang, Y., Zhou, J., Weng, J., & Feng, B. (2021) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/ac251f · Cited by 17

Emerging Cancer Vaccines: The Promise of Genetic Vectors

Aurisicchio, L., & Ciliberto, G. (2011) · Cancers · doi:10.3390/cancers3033687 · Cited by 16

Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy

Bell, R. B., Gough, M. J., Seung, S. K., Jutric, Z., Weinberg, A. D., Fox, B. A., Crittenden, M. R., Leidner, R. S., & Curti, B. D. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.08.020 · Cited by 16

Quantitative proteome analysis of overexpressed Cripto-1 tumor cell reveals 14-3-3γ as a novel biomarker in nasopharyngeal carcinoma

Wu, Z., Weng, D., & Li, G. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.03.001 · Cited by 16

Lack of Functional Selectin Ligand Interactions Compromises Long Term Tumor Protection by CD8+ T Cells

Stark, F. C., Gurnani, K., Sad, S., & Krishnan, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032211 · Cited by 16

TLR4-mediated immunomodulatory properties of the bacterial metalloprotease arazyme in preclinical tumor models

Pereira, F. V., de Melo, A. C. L., de Melo, F. M., Mourão‐Sá, D., Silva, P., Berzaghi, R., Herbozo, C. D. A., Coelho-dos-Reis, J. G. A., Scutti, J. A. B., Origassa, C. S. T., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1178420 · Cited by 16

Fast Single-Use VLP Vaccine Productions Based on Insect Cells and the Baculovirus Expression Vector System: Influenza as Case Study

Eibl, R., Steiger, N., Wellnitz, S., Vicente, T., John, C., & Eibl, D. (2013) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2013_186 · Cited by 15

Biomarker use is Associated with Reduced Clinical Trial Failure Risk in Metastatic Melanoma

Rubinger, D. A., Hollmann, S., Serdetchnaia, V., Ernst, D. S., & Parker, J. L. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.14.80 · Cited by 15

The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure

Zhou, T., Peng, J., Hao, Y., Shi, K., Zhou, K., Yang, Y. S., Yang, C., He, X., Chen, X., & Qian, Z. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.09.002 · Cited by 15

The CD3-Zeta Chimeric Antigen Receptor Overcomes TCR Hypo-Responsiveness of Human Terminal Late-Stage T Cells

Rappl, G., Riët, T., Awerkiew, S., Schmidt, A., Hombach, A. A., Pfister, H., & Abken, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030713 · Cited by 15

Immunocombination Therapy for High-Risk Neuroblastoma

Kroesen, M., Lindau, D., Hoogerbrugge, P. M., & Adema, G. J. (2012) · Immunotherapy · doi:10.2217/imt.11.169 · Cited by 14

The Metastatic Microenvironment

Maman, S., & Witz, I. P. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_2 · Cited by 14

Bugs as Drugs: Neglected but a Promising Future Therapeutic Strategy in Cancer

Divyashree, M., Prakash, S. K., Aditya, V., Aljabali, A. A. A., Alzahrani, K. J., Azevedo, V., Goés‐Neto, A., Tambuwala, M. M., & Barh, D. (2022) · Future Oncology · doi:10.2217/fon-2021-1137 · Cited by 13

Emerging Frontiers in Colorectal Cancer Therapy: From Targeted Molecules to Immunomodulatory Breakthroughs and Cell-Based Approaches

Fatemi, N., Mirbahari, S. N., Tierling, S., Sanjabi, F., Shahrivari, S., AmeliMojarad, M., AmeliMojarad, M., Rezaei, M. M., Nobaveh, P., Totonchi, M., et al. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08774-2 · Cited by 14

Immunotherapy in colorectal cancer: What have we learned so far?

Sánchez‐Castañón, M., Er, T., Bujanda, L., & Herreros‐Villanueva, M. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.06.027 · Cited by 14

Current Status of Immunotherapy Treatments for Pancreatic Cancer

Jiménez‐Luna, C., Prados, J. C., Ortíz, R., Melguizo, C., Torres, C., & Caba, O. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000623 · Cited by 13

Liposomes with cyclodextrin channels and polyethyleneimine (PEI) improves cytoplasmic vaccine delivery and induces anti-cancer immune activity in mice

Lee, A., Dadhwal, S., Gamble, A. B., & Hook, S. M. (2020) · Journal of Liposome Research · doi:10.1080/08982104.2020.1831016 · Cited by 13

Adoptive Immunotherapy of Advanced Melanoma

Shapira‐Frommer, R., & Schachter, J. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0203-7 · Cited by 13

Targeting the Immune System in the Treatment of Non-Small-Cell Lung Cancer

Rangachari, D., & Brahmer, J. (2013) · Current Treatment Options in Oncology · doi:10.1007/s11864-013-0250-8 · Cited by 15

In vivo investigation of twin-screw extruded lipid implants for vaccine delivery

Even, M.-P., Young, K., Winter, G., Hook, S. M., & Engert, J. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.02.014 · Cited by 13

Enhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent

Diab, A. K., Jenq, R. R., Rizzuto, G. A., Cohen, A. D., Huggins, D., Merghoub, T., Engelhorn, M. E., Guevara-Patino, J. A., Suh, D. Y., Hubbard-Lucey, V. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082496 · Cited by 12

T Cells as Vehicles for Cancer Vaccination

Bear, A. S., Cruz, C. C., & Foster, A. E. (2011) · BioMed Research International · doi:10.1155/2011/417403 · Cited by 12

Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen

Shen, H., Shao, H., Chen, X., Wu, F., Wang, H., Huang, Z., Shen, J., Wang, T., Zhang, W., & Huang, S. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1323-4 · Cited by 12

Rationale for combination of radiation therapy and immune checkpoint blockers to improve cancer treatment

Dahl, O., Dale, J. E., & Brydøy, M. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1554259 · Cited by 13

Melanoma Vaccines

Yang, J. C. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325f72 · Cited by 11

Challenges in the research and development of new human vaccines

Barbosa, T., & Barral‐Netto, M. (2013) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20131873 · Cited by 11

Immunotherapy of Cancer (Review)

Yuzhakova, D. V., Shirmanova, M. V., Sergeeva, T. F., Вадимовна, З. Е., & Lukyanov, K. A. (2016) · Современные технологии в медицине · doi:10.17691/stm2016.8.1.23 · Cited by 11

Clinical significance of immunotherapy with combined three kinds of cells for operable colorectal cancer

Du, X., Liu, H., Li, L., Xia, S., Ning, N., Zou, Z.-Y., Teng, D., Xiao, C., Li, R., & Xu, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-3242-4 · Cited by 11

Immunotherapy

Bell, R. B., Feng, Z., Bifulco, C. B., Leidner, R. S., Weinberg, A. D., & Fox, B. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-26568-3.00015-4 · Cited by 12

Harnessing the immune system for the treatment of melanoma: current status and future prospects

Guennoun, A., Sidahmed, H., Maccalli, C., Seliger, B., Marincola, F. M., & Bedognetti, D. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1176529 · Cited by 10

Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific T cells

Seidel, R. D., Merazga, Z., Thapa, D. R., Soriano, J., Spaulding, E. Y., Vakkasoglu, A. S., Ruthardt, P., Bautista, W., Quayle, S. N., Kiener, P. A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98716-z · Cited by 10

QS-21: Structural insights, immunological mechanisms, and prospects for rational design of safer vaccine adjuvants

Hu, Y., Wu, Y., Liu, H., Cheng, S., Wen, F., & Wan, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118223 · Cited by 9

Transgene IL-6 Enhances DC-Stimulated CTL Responses by Counteracting CD4+25+Foxp3+ Regulatory T Cell Suppression via IL-6-Induced Foxp3 Downregulation

Bhanumathy, K. K., Zhang, B., Ahmed, K. A., Qureshi, M., Xie, Y., Tao, M., Tan, X., & Xiang, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15045508 · Cited by 9

Regulatory considerations for clinical development of cancer vaccines

Heelan, B. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.982999 · Cited by 9

IL-10: Expanding the Immune Oncology Horizon

Chan, I. H., Wu, V. H., McCauley, S., Grimm, E. A., & Mumm, J. B. (2015) · Receptors & Clinical Investigation · doi:10.14800/rci.1041 · Cited by 9

In vitro-activated tumor-specific T lymphocytes prolong the survival of patients with advanced gastric cancer: a retrospective cohort study

Yang, F., Kuai, J., Li, G.-J., Fang, X.-J., & Gao, B.-Q. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s102909 · Cited by 9

Immunotherapy of Cancer

Davar, D., Tarhini, A. A., & Kirkwood, J. M. (2017) · doi:10.1002/9781119468868.ch20 · Cited by 9

Enhancing Human Immunodeficiency Virus-Specific CD8+ T Cell Responses with Heteroclitic Peptides

Adegoke, A., & Grant, M. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00377 · Cited by 8

Lonely killers

Fernández‐Marrero, Y., & López‐Requena, A. (2011) · mAbs · doi:10.4161/mabs.3.6.17770 · Cited by 8

Role of Cellular Biomolecules in Screening, Diagnosis and Treatment of Colorectal Cancer

Mei, X.-L., & Zheng, Q.-F. (2019) · Current Drug Metabolism · doi:10.2174/1389200220666191018153428 · Cited by 7

Therapeutic cancer vaccines: Advancements, challenges, and prospects

Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597

A review on cancer vaccines: Current developments and future prospects

CHANDANA, J. V. S., Renu, J., Swathi, E., Varsha, D., & RAMARAO, T. (2025) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2025.21.1.1018 · Cited by 1

Next-generation cancer vaccines and emerging immunotherapy combinations

Brandenburg, A., Heine, A., & Brossart, P. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.003 · Cited by 52

Therapeutic Cancer Vaccines: Mechanisms, Clinical Evidence and Translational Challenges

Nasika, R. (2026) · American journal of student research. · doi:10.70251/hyjr2348.42215222

Therapeutic cancer vaccines: development, challenges, and future perspectives

Di, D., Li, L.-F., He, T.-Y., Cui, H.-X., Nian, Y., Jiao, X., Han, C.-Y., & Wei, M. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01928-0 · Cited by 1